Commentary|Videos|October 28, 2024
Preclinical CNS Data for Zidesamtinib and Other ROS1 Inhibitors
Author(s)Benjamin Besse, MD, Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Advertisement
Episodes in this series
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing [email protected], or by calling 833-315-2722.
Advertisement
Related to this article
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.
A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain
Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
2
Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026
3
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
4
Docirbrutinib Yields High Response Rates in MCL and CLL
5